Nindanib 100 mg Tablet

Composition of Nindanib 100 mg Tablet

Nindanib 100 mg Tablet contains Nintedanib 100 mg (as nintedanib esylate) tablet. It belongs to the Tyrosine kinase inhibitor (VEGFR/FGFR/PDGFR inhibitor) class of medicines.

Uses of Nindanib 100 mg Tablet

Treatment of idiopathic pulmonary fibrosis (IPF); other progressive fibrosing interstitial lung diseases (ILDs) and systemic sclerosis–associated ILD (SSc-ILD) where prescribed; may also be used in combination with docetaxel for advanced non‑small cell lung cancer (NSCLC) after first‑line chemotherapy (as per specialist advice).

Key benefits

• Slows decline in lung function in IPF
• Helps reduce progression of fibrosing ILD/SSc-ILD when indicated
• Targets pathways involved in lung scarring
• Oral targeted therapy under specialist supervision

How Nindanib 100 mg Tablet works

Nintedanib is a tyrosine kinase inhibitor that blocks multiple receptors involved in fibrosis and abnormal vessel growth, including VEGFR, FGFR and PDGFR. By inhibiting these pathways it slows fibroblast activity and tissue scarring in the lungs, helping to reduce decline in lung function.

How to take Nindanib 100 mg Tablet

Oral tablet/capsule equivalent: take exactly as prescribed by a specialist. Usually taken twice daily about 12 hours apart with food and swallowed whole with water; do not crush or chew. If a dose is missed, skip it and take the next dose at the usual time; do not double the dose.

Take it exactly as your doctor prescribed. Do not change the dose or stop early on your own.

Missed dose and overdose

If you miss a dose

Take it as soon as you remember. If your next dose is almost due, skip the one you missed — never take two doses together to catch up.

If you take too much

An overdose of this medicine can cause a racing heart, tremor and marked restlessness. Do not wait for symptoms to appear — go to the nearest emergency department and take the pack or strip with you.

Side effects of Nindanib 100 mg Tablet

Most side effects of Nindanib are mild and settle as the body adjusts. Reported side effects include:

• Diarrhoea
• nausea
• vomiting
• abdominal pain
• decreased appetite
• weight loss
• increased liver enzymes (ALT/AST)
• headache
• fatigue

Stop the medicine and seek help immediately for a rash, swelling of the face or lips, wheezing or difficulty breathing. Tell your doctor about any side effect that persists or worries you.

Safety advice for Nindanib 100 mg Tablet

Warnings and precautions

Prescription-only anticancer/antifibrotic medicine. Liver toxicity: monitor LFTs before and during treatment; dose interruption/reduction may be needed. Diarrhoea and dehydration can be serious—start antidiarrhoeal therapy and maintain fluids. Increased risk of bleeding; use caution in patients on anticoagulants/antiplatelets or with bleeding disorders. Risk of arterial thromboembolic events; caution in patients with cardiovascular disease. Gastrointestinal perforation and impaired wound healing reported—use caution around surgery. Not recommended in severe hepatic impairment; caution in moderate hepatic impairment. Contraindicated in pregnancy; effective contraception required during treatment and for a period after stopping as advised by doctor.

Do not take Nindanib if

Not for anyone with a known allergy to this medicine or to any ingredient in the pack.

Interactions with other medicines

P-glycoprotein (P-gp) and CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin) may increase nintedanib levels; P-gp/CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, St John’s wort) may decrease effect. Additive bleeding risk with anticoagulants (warfarin, heparins, DOACs) and antiplatelets (aspirin, clopidogrel). Caution with hepatotoxic drugs due to increased liver injury risk.

How to store Nindanib 100 mg Tablet

Store at room temperature (below 25°C), protected from moisture and light. Keep in original pack and out of reach of children.

Expert advice for Nindanib 100 mg Tablet

Do not stop a preventive medicine because you feel well.

Manufacturer and class

Manufacturer:

GLENMARK PHARMACEUTICALS

Therapeutic class:

Antifibrotic / Antineoplastic (targeted therapy)

Drug class:

Tyrosine kinase inhibitor (VEGFR/FGFR/PDGFR inhibitor)